• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人乳头瘤病毒疫苗接种年龄。

Age for HPV vaccination.

作者信息

Harper Diane M, Paavonen Jorma

机构信息

Dartmouth College, Department of Women's and Gender Studies, Obstetrics and Gynecology, Community and Family Medicine, Hanover, NH, USA.

出版信息

Vaccine. 2008 Mar 14;26 Suppl 1:A7-11. doi: 10.1016/j.vaccine.2008.01.013.

DOI:10.1016/j.vaccine.2008.01.013
PMID:18642467
Abstract

HPV vaccination of pre-pubescent girls will be effective for many girls. Vaccinating girls and women older than 12 years of age may accelerate the reduction in cervical cancer rates. Currently HPV vaccines are effective for at least 5 years in the prevention of HPV 16 and 18 associated precancerous lesions however the duration of vaccine protection is unknown. The need for booster shots must therefore be addressed with patients as unknown. Continued cervical cancer screening is necessary regardless of vaccination. Vaccination alone will not eliminate cervical cancer.

摘要

对青春期前女孩进行人乳头瘤病毒(HPV)疫苗接种对许多女孩将是有效的。对12岁以上的女孩和妇女进行疫苗接种可能会加速宫颈癌发病率的降低。目前,HPV疫苗在预防HPV 16和18相关癌前病变方面至少5年有效,然而疫苗保护的持续时间尚不清楚。因此,必须向患者说明加强注射的必要性尚不清楚。无论是否接种疫苗,持续进行宫颈癌筛查都是必要的。仅靠接种疫苗并不能消除宫颈癌。

相似文献

1
Age for HPV vaccination.人乳头瘤病毒疫苗接种年龄。
Vaccine. 2008 Mar 14;26 Suppl 1:A7-11. doi: 10.1016/j.vaccine.2008.01.013.
2
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).四价人乳头瘤病毒疫苗:免疫实践咨询委员会(ACIP)的建议
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
3
Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.在宫颈癌发病率高和筛查覆盖率低的情况下,HPV 疫苗接种的成本效益。
Vaccine. 2017 Nov 1;35(46):6329-6335. doi: 10.1016/j.vaccine.2017.08.083. Epub 2017 Sep 9.
4
Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.比利时对女孩进行宫颈癌疫苗接种的成本效益评价:性活跃前和性活跃后的影响
Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.
5
Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.评估荷兰针对青春期前女孩引入人乳头瘤病毒普遍接种疫苗的情况。
Vaccine. 2007 Aug 14;25(33):6245-56. doi: 10.1016/j.vaccine.2007.05.061. Epub 2007 Jun 21.
6
Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.为年轻成年女性接种预防性四价人乳头瘤病毒(HPV 型 6、11、16 和 18)疫苗的益处。
Vaccine. 2010 Nov 29;28(51):8065-72. doi: 10.1016/j.vaccine.2010.10.017. Epub 2010 Nov 16.
7
Prophylactic HPV vaccination for the prevention of cervical cancer.预防性人乳头瘤病毒疫苗用于预防宫颈癌。
Hawaii Med J. 2007 Jul;66(7):190-1.
8
Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.人乳头瘤病毒(HPV)预防性疫苗接种:对公共卫生的挑战及对筛查的影响
Vaccine. 2007 Apr 20;25(16):3007-13. doi: 10.1016/j.vaccine.2007.01.016. Epub 2007 Jan 18.
9
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.芬兰人乳头瘤病毒16型与宫颈癌的流行病学及疫苗接种的潜在影响:数学建模分析
PLoS Med. 2006 May;3(5):e138. doi: 10.1371/journal.pmed.0030138. Epub 2006 Apr 4.
10
[Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues].[宫颈癌的预防(二):预防性人乳头瘤病毒疫苗、现有知识、实际操作及新问题]
Presse Med. 2007 Apr;36(4 Pt 2):640-66. doi: 10.1016/j.lpm.2007.02.004. Epub 2007 Mar 12.

引用本文的文献

1
Prevalence and determinants of oral and cervicogenital HPV infection: Baseline analysis of the Michigan HPV and Oropharyngeal Cancer (MHOC) cohort study.口腔和宫颈 HPV 感染的流行率及决定因素:密歇根 HPV 和口咽癌(MHOC)队列研究的基线分析。
PLoS One. 2022 May 16;17(5):e0268104. doi: 10.1371/journal.pone.0268104. eCollection 2022.
2
Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.斯威士兰人乳头瘤病毒相关宫颈疾病和尖锐湿疣的成本分析
PLoS One. 2017 May 22;12(5):e0177762. doi: 10.1371/journal.pone.0177762. eCollection 2017.
3
Cross sectional study investigating the differences in knowledge and behaviors about HPV between vaccinated and non-vaccinated girls.
一项横断面研究,调查接种疫苗和未接种疫苗的女孩在人乳头瘤病毒(HPV)知识和行为方面的差异。
J Prev Med Hyg. 2016 Sep;57(3):E121-E127.
4
Reasons for receiving or not receiving HPV vaccination in primary schoolgirls in Tanzania: a case control study.坦桑尼亚小学女生接种或未接种 HPV 疫苗的原因:病例对照研究。
PLoS One. 2012;7(10):e45231. doi: 10.1371/journal.pone.0045231. Epub 2012 Oct 24.
5
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.下一代癌症防护:适用于女性的二价人乳头瘤病毒疫苗
ISRN Obstet Gynecol. 2011;2011:457204. doi: 10.5402/2011/457204. Epub 2011 Nov 2.
6
Factors influencing familial decision-making regarding human papillomavirus vaccination.影响人乳头瘤病毒疫苗接种家庭决策的因素。
J Pediatr Psychol. 2010 Aug;35(7):704-15. doi: 10.1093/jpepsy/jsp108. Epub 2009 Dec 4.